2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : ÇÏÀ̺긮µå (Àå¼Ò: ¹é¹ü±è±¸±â³ä°ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) 2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462
À̸ÞÀÏ :
secretkda@thedementia.co.kr ±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í ÀϹÝȸ¿ø 2¸¸¿ø, Á¤È¸¿ø 3¸¸¿ø, ºñȸ¿ø 5¸¸¿ø (ÇöÀåµî·Ï ¾øÀ½)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 08:50~09:00 Opening remarks ()
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:00~09:20 Genetics Update ¹Ú¿µÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:20~09:40 Microbiome Update ÀÌ°ÇÈ£(Á¶¼±´ëÇб³)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:40~10:05 The Gantenerumab Global Development Program for Alzheimer''''s Disease Scott Schobel(Roche)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:05~10:30 Clinical, Biomarker, and Safety Update BAN2401-G000-201, the Lecanemab Phase 2 Proof of Concept Study and Open Label Extension Chad Swanson(Eisai)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:30~10:55 Future for the development of Alzheimer¡¯s disease modifiers clinical trial results of donanemab Ena Oru(Lilly)
ÈÞ½Ä 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:20 Coffee Break ()
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:20~12:00 Can we prevent aging? ÇѼ³Èñ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:00~12:40 Current and future direction of AD biomarkers Gill Rabinovici(UCSF)
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:40~13:00 ÃÑȸ ()
½Ä»ç 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:00~14:20 Lunch ¹× Poster session ()
Åä·Ð 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:20~15:20 Pannel discussion for Current Issues : Aducanumab! Is this new hope for Alzhiemer's? ¹Ú±âÇü(°¡ÃµÀÇ´ë)
ÈÞ½Ä 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:20~15:30 Coffee Break ()
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:30~15:50 Development of tau-targeted therapeutic strategy for dementia ±èÀ±°æ(KIST)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:50~16:10 Nanobiosensor technology for serological biomarker detection of neurodegenerative disease Ȳ±³¼±(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:10~16:30 Genetic factors of Alzheimer's disease in the Korean population ±èÈñÁø(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:30~16:40 Coffee Break ()
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:40~17:00 Clinical usefulness and need of blood biomarkers in the diagnosis and follow-up of AD °í¼ºÈ£(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:00~17:20 Introduction of Currently Available Blood Based Biomarker of AD ÀåÀç¿ø(°¿øÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:20~17:40 Clinical application of AD blood biomarker: expectations & concerns ½É¿ë¼ö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:30~15:50 Clinical application of A.I. in Dementia ¼»ó¿ø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:50~16:10 A.I in Neuroimaging of AD Á¤¿ë(KAIST)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:10~16:30 Dementia big data platforms in the UK, Europe and Korea ±èÄ¡Çå(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:30~16:40 Coffee Break ()
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:40~17:00 µðÁöÅÐ Ä¡·áÁ¦ÀÇ Çö¾È°ú ¹Ì·¡ ÇÑ¿µ¹Î ÁÖ¹«°ü(½ÄÇ°ÀǾàÇ°¾ÈÀüó)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:00~17:20 µðÁöÅÐ Ä¡·áÁ¦ °³¹ß°ú ÇâÈÄ Àü¸Á ±èÁø¿ì ´ëÇ¥(¢ßÇÏÀÌ)
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:20~17:40 µðÁöÅÐÇコÄɾî/µðÁöÅÐÄ¡·áÁ¦´Â ¾î¶»°Ô ºñÁö´Ï½º°¡ µÇ´Â°¡ ±èÄ¡¿ø »ó¹«(Ä«Ä«¿Àº¥Ã³½º)
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 17:40~17:50 Closing remarks ¹× ½Ã»ó½Ä ()